Evidence map›Paper›PMID 16322523›Full record

ArticleGenetics2006

The Saccharomyces cerevisiae phosphatase activator RRD1 is required to modulate gene expression in response to rapamycin exposure.

Julie Douville, Jocelyn David, Karine M Lemieux, Luc Gaudreau, Dindial Ramotar

Open access · bronzeAbstract read
In one paragraph

Article in Genetics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Julie DouvilleDépartement de Biologie, Université de Sherbrooke, Quebec, Canada.
Jocelyn David
Karine M Lemieux
Luc Gaudreau
Dindial Ramotar
Université de Montréal · CAUniversité de Sherbrooke · CAHôpital Maisonneuve-Rosemont · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We show that mutants lacking either the phosphatase activator Rrd1 or the phosphatase Pph3 are resistant to rapamycin and that double mutants exhibit a synergistic response. This phenotype could be related to an inability of the mutants to degrade RNA polymerase II, leading to transcription of critical genes that sustain growth.

Indexed as

Antifungal AgentsBlotting, NorthernGene Expression Regulation, FungalIntracellular Signaling Peptides and ProteinsMutationPeptidylprolyl IsomerasePhosphoprotein PhosphatasesSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSirolimusAntifungal AgentsIntracellular Signaling Peptides and ProteinsPeptidylprolyl IsomerasePhosphoprotein PhosphatasesPPH3 protein, S cerevisiaeRRD1 protein, S cerevisiaeSaccharomyces cerevisiae ProteinsSirolimus

Identifiers

PMID16322523
PMCPMC1456220
OpenAlexW2162089457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.